İntravenöz ve Subkütan İmmünoglobulin Replasman Tedavisi Kullanan Hastalarda Sağlık Durumu ve Yaşam Kalitesinin Değerlendirilmesi

Year 2022, Volume: 75 Issue: 1, 77 - 83, 30.06.2022

Saliha Esenboğa , Ayşegül Akarsu , Hacer Neslihan Bildik Deniz Ayvaz , İlhan Tezcan

https://doi.org/10.4274/atfm.galenos.2022.55476

Abstract

Objectives: Health-related quality of life (HRQoL) is an emerging field of research in primary immunodeficiency (PID) patients. PID patients’ quality
of life worsens as a result of their considerable disease load causing limited capacity to work and attend school, as well as participation in routine
physical activities. The aim of this study was to analyze the demographics, treatment satisfaction, treatment-related side effects, health status and
HRQoL of adult PID patients using different immunoglobulin replacement methods.

Materials and Methods: In this prospective, cross-sectional research, 53 adult patients, who had been diagnosed with PID and treated with IgRT,
were included. The Euro-QOL 5-D (EQ-5D) and Medical Outcomes Study Short Form-36 (SF-36) scales were used to evaluate health status and
HRQoL.

Results: The study included 53 patients with a median age of 32 (IQR: 24-45) years. Thirty-three (62.2%) patients were female. Twenty-three
individuals received intravenous immunoglobulin (IVIG) and 30 subcutaneous immunoglobulin (SCIG). There was no significant difference in side
effects between SCIG and IVIG. According to the EQ-5D results, anxiety/depression was the most problematic area to deal with. Patients’ median
SF-36 scores were significantly lower (p<0.005) than healthy Turkish population norms in all categories (except for mental health). For physical
functioning, physical role difficulty, emotional role difficulty, and vitality, the median scores of the SCIG group were similar to those of the healthy
population.

Conclusion: Given that individuals receiving SCIG therapy have a comparable quality of life as the general population, employing SCIG in appropriate
and chosen patients may improve quality of life by allowing patients to be more independent. Patients with PIDs should have regular HRQoL
assessments to ensure that they are receiving sufficient psychosocial care.

Keywords

: Health Status , Quality of Life , Primary Immunodeficiency , IVIG , SCIG

Ethical Statement

Ethics Committee Approval: This study was approved by the Ethics Committee of Hacettepe University Faculty of Medicine (GO-21/1238). Informed Consent: Informed consent was taken from all patients and/or their parents as well. Peer-review: Externally peer-reviewed

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Osterfeld E. Aristotle on the good life and quality of life. In: Nordenfelt L (ed.), Concepts and Measurement of Quality of Life in Health Care. Amsterdam: Kluwer.; 1994. s. 19-34.
• 2. Hellström Y, Hallberg IR. Perspectives of elderly people receiving home help on health, care and quality of life. Health Soc Care Community. 2001;9:61- 71.
• 3. Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol. 2020;40:66-81.
• 4. Aghamohammadi A, Montazeri A, Abolhassani H, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol. 2011;10:47-51.
• 5. Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clin Immunol. 2015;11:27.
• 6. EuroQol Group. EuroQol--a new facility for the measurement of healthrelated quality of life. Health Policy. 1990;16:199-208.
• 7. Eser E, Dinç G, Cambaz S, et al. EURO-QoL (EQ-5D) indeksinin toplum standartları ve psikometrik özellikleri: Manisa kent toplumu örneklemi. 2. Sağlıkta Yaşam Kalitesi Kongresi Bildiri Özetleri Kitabı Meta Basımevi.; İzmir: 2007. s. 78.
• 8. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF36). I. Conceptual framework and item selection. Med Care. 1992;30:473- 483.
• 9. Koçyiğit H, Aydemir Ö, Ölmez N, et al. Kısa Form-36 (KF- 36)’nın Türkçe Versiyonunun Güvenilirliği ve Geçerliliği. İlaç ve Tedavi Dergisi. 1999;12:102- 106.
• 10. Demiral Y, Ergor G, Unal B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health. 2006;6:247.
• 11. Routes J, Costa-Carvalho BT, Grimbacher B, et al. Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment. J Clin Immunol. 2016;36:450-461.
• 12. Zhang S, Kline M, Fuleihan RL, et al. PROMIS-29 survey confirms major impact of fatigue on health-related quality of life in common variable immunodeficiency. Immunol Res. 2020;68:379-388.
• 13. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs. 2013;73:1307-19.
• 14. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics. 1996;98:1127-31. 15. Quinti I, Di Pietro C, Martini H, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J. 2012;53:603-10.
• 16. Ataeinia B, Montazeri A, Tavakol M, et al. Measurement of Health-Related Quality of Life in Primary Antibody-Deficient Patients. Immunol Invest. 2017;46:329-340.